Table 4 Clinical factors for renal function decrease
From: Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients
Patient | Group D 13 (37.5%) | Group ND 27 (62.5%) | p-value |
|---|---|---|---|
[background factors] | |||
Age, median [range] | 66 [46–76] | 69 [33–78] | 0.1650 |
Sex, male (%) | 2 (15.4) | 11 (40.7) | 0.0951 |
BW (kg), median [range] | 57.9 [41.6–74.0] | 60.7 [35.3–97.1] | 0.4356 |
Histopathology, follicular (%) | 5 (38.4) | 10 (37.0) | 0.9306 |
Performance status, ≥ 1 | 6 (46.5%) | 11 (40.7%) | 0.7460 |
eGFR at baseline (mL/min/1.73 m2), median [range] | 78.5 [65.2–118.7] | 63.8 [43.6–119.1] | 0.0165 |
eGFR at baseline (mL/min/1.73 m2), < 60 | 0 (0) | 8 (29.6) | 0.0072 |
Proteinuria grade 1 at baseline, yes (%) | 2 (15.4) | 0 (0) | 0.0298 |
Past hypertension history (%) | 8 (61.5) | 16 (59.3) | 0.8903 |
Past diabetes mellitus history (%) | 1 (7.7) | 2 (7.4) | 0.9745 |
Past renal history (%) | 1 (7.7) | 5 (18.5) | 0.3452 |
Renal metastasis, (%) | 0 (0) | 3 (11.1) | 0.1158 |
Liver metastasis, (%) | 1 (7.7) | 6 (22.2) | 0.2296 |
[Treatment-related factors] | |||
Treatment period (months) | 34.1 [12.8–60.5] | 25.2 [6.8–61.5] | 0.0832 |
Observation period (months) | 45.4 [21.0–60.5] | 27.2 [7.4–61.5] | 0.0115 |
Dose intensity (mg/day), median [range] | 9.7 [4.1–14.0] | 9.46 [4.0–16.4] | 0.7398 |
Best response in RECIST criteria, PR (%) | 10 (76.9) | 19 (70.4) | 0.6606 |
Proteinuria grade 3, yes (%) | 10 (76.9) | 11 (40.7) | 0.0283 |
Treatment continuation, yes (%) | 8 (61.5) | 11 (40.7) | 0.2161 |
Treatment termination due to renal problem, yes (%) | 2 (15.4) | 5 (18.5) | 0.8053 |